3 completed, 1 unknown. 4 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 3, Unknown 1 |
| Phase 2 | 1 | Completed 1 |
Follow netupitant: new trials by email Literature Review of netupitant trials Research Report on netupitant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NEPA Combined With Olanzapine, Dexamethasone-sparing for the Effect of CINV in Patients Receiving HEC Regimens Netupitant / Palonosetron Oral Capsule [Akynzeo], Olanzapine, Dexamethasone Oral - Chemotherapy-induced Nausea and Vomiting, Highly Emetogenic Chemotherapy | Phase 3 | Completed | Fudan University | 644 | 2024-05-01 | 2026-04-09 |
| Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer Dexamethasone, Laboratory Biomarker Analysis, Netupitant/Palonosetron Hydrochloride - Breast Carcinoma | Phase 3 | Completed | University of Rochester NCORP Research Base | 1363 | 2018-04-19 | 2025-09-25 |
| Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer Netupitant, Palonosetron, Palonosetron Hydrochloride - Malignant Neoplasm, Nausea | Phase 2 / Phase 3 | Completed | M.D. Anderson Cancer Center | 53 | 2017-05-03 | 2023-10-17 |
| Dexamethasone-sparing Approach Including NEPA Against Emesis Caused by Cisplatin Netupitant/Palonosetron, Dexamethasone - Chemotherapy-induced Nausea and Vomiting | Phase 3 | Unknown | Consorzio Oncotech | 261 | 2016-11-25 | 2020-04-03 |
Vomiting (3) · Nausea (2) · Breast Neoplasms (1) · Lung Neoplasms (1) · Neoplasms (1)
Consorzio Oncotech (1) · Fudan University (1) · M.D. Anderson Cancer Center (1) · University of Rochester NCORP Research Base (1)
United States (2) · China (1) · Italy (1)
David Hui (1) · Emilio Bria, MD (1) · Jian Zhang, MD,PhD (1) · Luigi Celio, MD (1) · Luke Peppone (1)
PMID 33388382, PMID 35999527, PMID 36690734, PMID 37290207, PMID 38433125, PMID 42241642
R01CA200579 (1), UG1CA189961 (1)